Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease‐modifying treatments—EQ‐5D data from the Swedish BioFINDER study-Reference-Cited by-同舟云学术

Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease‐modifying treatments—EQ‐5D data from the Swedish BioFINDER study

Published:2021-05-13 Issue:11 Volume:17 Page:1832-1842
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Gustavsson Anders¹²,Raket Lars Lau³⁴,Lilja Mathias¹,Rutten‐Jacobs Loes⁵,Fues Wahl Hanna¹,Bagijn Marloes⁶,Stomrud Erik⁷⁸,Hansson Oskar⁷⁸,Palmqvist Sebastian⁷⁸

Affiliation:

1. Quantify Research Stockholm Sweden

2. Department of Neurobiology Care Sciences and Society Karolinska Institute Stockholm Sweden

3. H. Lundbeck A/S Copenhagen Denmark

4. Clinical Memory Research Unit Lund University Lund Sweden

5. Product Development Personalized Health Care F. Hoffmann‐La Roche Ltd. Basel Switzerland

6. Roche Products Ltd Welwyn Garden City UK

7. Clinical Memory Research Unit Clinical Sciences Malmö Lund University Malmö Sweden

8. Memory Clinic Skåne University Hospital Malmö Sweden

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12355

Reference37 articles.

1. Preparing the health‐care system to pay for new Alzheimer's drugs

2. Alzheimer's disease drug development pipeline: 2019

3. Alzheimers Dement 2020 Alzheimer's Association 2020 Alzheimer's disease facts and figures

4. Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease;Alzheimer's Research & Therapy;2024-02-29

2. Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment;The Journal of Prevention of Alzheimer's Disease;2024

4. Disease severity and mortality in Alzheimer's disease: an analysis using the U.S. National Alzheimer’s Coordinating Center Uniform Data Set;BMC Neurology;2023-08-14

5. A longitudinal study on quality of life along the spectrum of Alzheimer’s disease;Alzheimer's Research & Therapy;2022-09-15